Cytotoxicity testing is an integral part of the required biological evaluation for nearly all medical devices according to ISO 10993-1. Typically, medical device extracts are evaluated to estimate the biological impact of potential leachable substances that may be released from the device during clinical use. For extract-based cytotoxicity assays, extracts are prepared using cell culture media under exaggerated conditions (i.e., with agitation at elevated temperatures for extended periods) to enhance the identification of possible toxicological risks. Cytotoxicity describes the ability of a substance to inflict damage or result in the death of living cells. Cytotoxic agents can trigger various cellular responses including slowing cell growth, causing cell death, and interfering with the cell’s metabolism or structural integrity – but can the measurements of cell toxicity in a Petri dish (or multi-well plate) predict the overall biological safety of a medical device?
For decades, researchers have been working to determine if links between cytotoxicity and in vivo endpoints exist. The chemical industry was first to research the relationship between cytotoxicity and in vivo biological effects and began applying the apparent correlation to toxicity screening. In 2006, the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the European Centre for the Validation of Alternative Methods (ECVAM) conducted a validation study to characterize two in vitro cytotoxicity assays for determining starting doses for rodent acute oral toxicity studies. This work resulted in high quality in vivo lethality and in vitro cytotoxicity reference databases and refinement of LD50 values for many reference substances but ultimately demonstrated that cytotoxicity assays are not sufficiently accurate to correctly predict rodent acute oral toxicity. Cytotoxicity assays are prone to sometimes overpredict the toxicity of the least toxic substances and underpredict the toxicity of the most toxic substances. Why the apparent disconnect?
Classic cell assays capture straightforward cytotoxic effects but miss complex interactions. A leachable that might be diluted, metabolized, or excreted in vivo can damage a vulnerable cell monolayer in vitro. This sensitivity means false positives are common. Cytotoxicity assays often flag extracts that would never actually cause harm in a patient. At the same time, some biological reactions in vivo (such as an immune-mediated allergy) don’t manifest as cell death in vitro, leading to occasional false negatives – non-cytotoxic materials occasionally still trigger a sensitizing effect or cause systemic toxicity through other mechanisms which are not reflected in in vitro assays. Additional considerations include:
In other words, a “cytotoxic” result in vitro does not mean a medical device is toxic in vivo, and conversely, a non-cytotoxic result doesn’t guarantee absence of irritation or other effects. Does this mean that cytotoxicity testing is useless? Not at all…it remains an indispensable screening tool that is necessary, but not sufficient, for evaluating biological safety. Current regulations and standards already reflect this understanding:
In practice, when a cytotoxicity assay fails, next steps might include:
The key for regulators is documentation and expert analysis. In the Biological Evaluation Report, it must be explained how cytotoxicity failure was addressed: which chemicals were found, what their toxicological profiles are, and why, despite the in vitro result, the medical device is safe (or how the risk has been mitigated). If changes were made (e.g., added a rinse step to the cleaning process, changed a material, adjusted a sterilization method) to resolve cytotoxicity, those actions must be documented. Regulators do not automatically reject a device because of a cytotoxicity failure, but the scientific rationale provided for the result will be heavily scrutinized. The goal is to ensure patient safety with a minimum of unnecessary delays or tests.
MED Institute provides comprehensive biological risk assessment services to support the safety evaluation of medical devices in accordance with ISO 10993; our multidisciplinary team of professionals offers expert guidance on material characterization, biological equivalence assessment, toxicological evaluation of chemical constituents, and even support in responding to submission deficiencies. MED Institute technical experts have extensive experience in developing Biological Evaluation Plans/Reports in compliance with global regulatory standards and based on sound scientific principles. By engaging with our team of experts, several manufacturers have designed safer products and accelerated their regulatory submissions and successful market entry.
Contact us today to discuss your project needs 855.463.1633 | askmed@medinstitute.com | medinstitute.com.
OUR COMMITMENT
We are committed to consistently performing services with high quality, that deliver exceptional results, and add value to the client’s business.
For client surveys sent since 2025, we received ratings of 4.99/5 (16).